NEW YORK / TEL AVIV — 2018
RDD has completed enrollment to a pivotal Phase 3 study in Europe for the treatment of chronic anal fissure using RDD-1219 Capository™. In December 2017, an independent data monitoring committee reported no safety concerns and confirmed the company's sample size assumptions, recommending that no further enrollment is required.
RDD raised $9.54M in Series B funding in November 2017, of which $6M is from two new investors — Pharmascience, Inc. and Agate Medical Investments, an international life science fund. Existing investors OrbiMed and Capital Point also participated in this funding round.
Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.
Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.
Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).
Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.